Fresh frozen plasma

Global Rare Hemophilia Factors Market Analysis Report 2023-2030 - Tailored Factor Concentrates Gain FDA Approval, Fueling Rare Hemophilia Factors Market Growth

Retrieved on: 
Tuesday, October 3, 2023
Orphan Drug Act of 1983, Fresh frozen plasma, Infection, Hand, Prevalence, Personal protective equipment, Health care, COVID-19, Quality of life, Haemophilia, Coagulation, Second Continental Congress, Congress, Plasma, ODA, VII, Patient, Child, Coagulation factor VII, Factor VII deficiency, Growth, Diagnosis, FDA, Treatment, Speciality chemicals, Pharmaceutical industry, Safety, Tisagenlecleucel

The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.

Key Points: 
  • The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
  • The surge in the market is primarily attributed to the increased availability of tailored factor concentrates securing regulatory approvals, notably from the U.S. FDA.
  • Additionally, the rising adoption of prophylaxis treatment among patients is expected to be a significant growth driver in the coming years.
  • Prophylactic treatment is recommended for individuals with severe rare hemophilia factor disorders to prevent bleeding episodes and enhance their quality of life.

Sugarmade Announces Fully Executed LOI Toward Minority Stake Acquisition of Turnkey Cannabis Cultivation Property

Retrieved on: 
Thursday, June 30, 2022
Acquisition, CEO, Weather, GLOBE, Party, Company, Property, County, RMI, LOI, Fresh frozen plasma, OTC Markets Group, Cannabis, Private Securities Litigation Reform Act, Nature, Forward-looking statement, NUG, Bank, Drug, Security (finance)

The RMI acquisition follows the Companys recently announced collaborative cannabis cultivation contract with Cannabis Global, Inc. (OTC Pink: CBGL) (Cannabis Global) to produce approximately 25,000 pounds of Fresh Frozen cannabis, which Cannabis Global will use in its product lines for distribution throughout the California cannabis marketplace.

Key Points: 
  • The RMI acquisition follows the Companys recently announced collaborative cannabis cultivation contract with Cannabis Global, Inc. (OTC Pink: CBGL) (Cannabis Global) to produce approximately 25,000 pounds of Fresh Frozen cannabis, which Cannabis Global will use in its product lines for distribution throughout the California cannabis marketplace.
  • The LOI with RMI Ventures covers a minority stake acquisition that includes the associated real estate (the Property), cannabis-related licenses and the business operation.
  • The acquisition will include minority ownership of a 10-year cultivation license at the Property based on a cultivation canopy size and other information outlined in the license issued by the County of Lake, California.
  • The Property is located near the Companys recently acquired 640-acre cultivation property in Lake County, California, outside of the Commercial Cannabis Cultivation Exclusion Zones.

Sugamade Executes on Its Collaborative Cannabis Cultivation Strategic Model - Enters the ‘Fresh Frozen’ Cannabis Market via Contract Cultivation Contract with Cannabis Global, Inc.

Retrieved on: 
Wednesday, May 4, 2022
Frozen, Head, Forward-looking statement, THC, Humidity, Cannabis, GLOBE, Company, Flower, OTC Markets Group, Private Securities Litigation Reform Act, Marketing, Sale, Plant, Biomass, CEO, Fresh frozen plasma, Nature, Drug, Medicinal plants, Security (finance)

Fresh Frozen cannabis is cultivated to be immediately flash frozen upon harvest instead of the traditional treatment of drying and curing after harvest.

Key Points: 
  • Fresh Frozen cannabis is cultivated to be immediately flash frozen upon harvest instead of the traditional treatment of drying and curing after harvest.
  • Upon harvest, all cannabis plants will be trimmed with the best flowers immediately flash-frozen to preserve the delicate oil-containing trichomes.
  • This Fresh Frozen cannabis will then be stored at ultra-low temperatures until processed via 100% solventless extraction technologies.
  • In many ways, the advent of fresh Frozen-oriented cannabis cultivation has turned the cannabis cultivation model on its head.

Akron Biotech Signs Exclusive Global Agreement with Octapharma to Produce Virally Inactivated Human AB Serum Derived from Octaplas® for the Cell Therapy Market

Retrieved on: 
Wednesday, January 20, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Chemicals, Plastics, Manufacturing, Branches of biology, Anatomy, Body fluids, Blood, Transfusion medicine, Octapharma, Blood plasma, Fresh frozen plasma, Serum, Cell culture

Akron Biotechnology, LLC (Akron Biotech), today announced it has signed an exclusive global agreement to manufacture virally inactivated Human AB Serum for the cell therapy market using Octaplas, Octapharmas pooled, solvent-detergent treated human plasma.

Key Points: 
  • Akron Biotechnology, LLC (Akron Biotech), today announced it has signed an exclusive global agreement to manufacture virally inactivated Human AB Serum for the cell therapy market using Octaplas, Octapharmas pooled, solvent-detergent treated human plasma.
  • Switzerland-based Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
  • Human AB Serum converted from plasma is a critical media supplement used in cell therapy manufacturing.
  • Under the agreement, Akron Biotech will produce Human AB Serum converted from Octaplas, which is Octapharmas pooled, solvent/detergent treated human plasma product.

Global Hemophilia Markets, 2020-2026: Focus on Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others - ResearchAndMarkets.com

Retrieved on: 
Monday, November 30, 2020
Retail, Other Retail, Coagulation system, Body fluids, Anatomy, Haemophilia, Blood, Coagulation, Haemophilia B, Haemophilia A, Jeanne Lusher, Fresh frozen plasma

Global Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B, and, Others), By Therapy (Replacement Therapy, Gene Therapy, and Others), By Product Type (Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others) Forecast Period (2020-2026).

Key Points: 
  • Global Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B, and, Others), By Therapy (Replacement Therapy, Gene Therapy, and Others), By Product Type (Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others) Forecast Period (2020-2026).
  • The global hemophilia market is anticipated to grow at a CAGR of 6% during the forecast period.
  • Further, based on the product type, the market is subdivided into recombinant coagulation factor concentrates, plasma-derived coagulation, and other factor concentrates.
  • The global hemophilia market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World.

Biolog-id Italia Through Its Distributor PACO srl, Have Been Awarded by « Azienda Sanitaria Locale in Pescara » the Tender for Managing Labile Blood Products

Retrieved on: 
Tuesday, March 10, 2020
Medical devices, Health, Hospitals, Managed care, Research, Science, Branches of biology, Transfusion medicine, Anatomy, Blood products, Hematology, Blood bank, Blood plasma, Platelet, Blood, Fresh frozen plasma, Red blood cell, Azienda Sanitaria Locale in Pescara, Biolog-id

Following a manifestation of interest and the subsequent tender published in 2019 by the Azienda Sanitaria in Pescara, PACO srl, Biolog-ids distributor, was awarded the contract mid-January 2020 with the Biolog-id Transfusion solution for the management of labile Blood products!

Key Points: 
  • Following a manifestation of interest and the subsequent tender published in 2019 by the Azienda Sanitaria in Pescara, PACO srl, Biolog-ids distributor, was awarded the contract mid-January 2020 with the Biolog-id Transfusion solution for the management of labile Blood products!
  • The major Blood bank in Abruzzo region has signed a contract for 4 years to manage their stock of red blood cells concentrates, fresh frozen plasma & platelets.
  • The Solution will manage all the processes from blood collection to assignation to a patient and will trace the blood products transportations, including temperature control, between the Blood Bank storage and 2 remote hospitals.
  • In addition, all the Azienda Santirias processed Plasma products, to be used by the Plasma fractionation industry, will also be fully traced using the Biolog-id Plasma Processing Solution.

As Global Coronavirus Concerns Grow, Octaplas™ Provides Enhanced Safety Option

Retrieved on: 
Thursday, February 6, 2020
Infectious diseases, Biotechnology, Health, Transfusion medicine, Blood products, Viruses, Octapharma, Medical specialties, Medicine, Viral envelope, Fresh frozen plasma, Middle East respiratory syndrome-related coronavirus

Octaplas , Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, provides that peace of mind the healthcare community is looking for, said Octapharma USA President Flemming Nielsen.

Key Points: 
  • Octaplas , Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, provides that peace of mind the healthcare community is looking for, said Octapharma USA President Flemming Nielsen.
  • Octaplas offers an additional layer of protection in the manufacturing process, beginning with plasma pooling and cell filtration.
  • These steps are followed by S/D treatment, which is a proactive safety step designed to inactivate enveloped viruses, including unknown emerging viruses.
  • Statement from the Plasma Protein Therapeutics Association (PPTA), 2019 Novel Coronavirus (2019-nCoV) and Plasma Protein Therapies , January 29, 2020.

ZipThaw Receives FDA Clearance for Clinical Use

Retrieved on: 
Monday, January 6, 2020
Blood products, Transfusion medicine, Medical specialties, Anatomy, Body fluids, Plasma frozen within 24 hours, Fresh frozen plasma, Blood plasma, FFP, Plasma, Food and Drug Administration, Clearance

ZipThaw, used with the ZipSleeve anti-contaminant disposable barrier, is the world's first dry and portable precision plasma thawing system.

Key Points: 
  • ZipThaw, used with the ZipSleeve anti-contaminant disposable barrier, is the world's first dry and portable precision plasma thawing system.
  • ZipThaw and ZipSleeve have earned CE Mark, ISO certification, UL Listing and now FDA clearance for thawing fresh frozen plasma (FFP) and plasma frozen within 24 hours after phlebotomy (FP24).
  • "We are delighted with the FDA's clearance of ZipThaw as an effective and safe plasma thawing device for clinical use," said FreMon Scientific CEO Dr. Farideh Bischoff.
  • FreMon Scientific is cleared to sell ZipThaw and ZipSleeves in all FDA and CE Mark territories.

The global rare hemophilia factors market size is anticipated to reach USD 336.3 million by 2025

Retrieved on: 
Monday, May 21, 2018
Blood, Blood products, RTT, Anatomy, Fresh frozen plasma, Cryoprecipitate, Bleeding, Haemophilia, Jeanne Lusher

NEW YORK, May 21, 2018 /PRNewswire/ -- Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type, By Treatment (Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025

Key Points: 
  • NEW YORK, May 21, 2018 /PRNewswire/ -- Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type, By Treatment (Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025
    The global rare hemophilia factors market size is anticipated to reach USD 336.3 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.1% during the forecast period.
  • In addition, growing adoption of prophylaxis treatment by patients is expected to boost the growth of the market in coming years.
  • Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life.
  • Several key market players in the market are focusing on R&D to launch new products and solutions for the treatment of rare hemophilia factor disorders.